+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

U.S. Active Pharmaceutical Ingredients CDMO Market Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, ADC), By Synthesis, By Drug, By Workflow, By Application, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 80 Pages
  • June 2025
  • Region: United States
  • Grand View Research
  • ID: 6111436
Description Jump to:

Market Size & Trends

The U.S. active pharmaceutical ingredients CDMO market was valued at USD 25.28 billion in 2024 and is projected to reach USD 33.86 billion by 2030, growing at a CAGR of 5.1% from 2025 to 2030. This growth is driven by rising demand for advanced pharmaceutical manufacturing services to support the development of innovative drugs and therapies. In addition, increasing investments in biologics and high-potency APIs drive market expansion. The growing prevalence of chronic diseases and the need for efficient, scalable production solutions also contribute to the market’s momentum.

Key drivers supporting this market growth include technological advancements in process chemistry and manufacturing automation, which improve yield, reduce waste, and enhance product quality. Regulatory support encouraging outsourcing to specialized CDMOs is vital, as these organizations help ensure compliance with stringent FDA and international standards. The increasing focus on personalized medicine and novel therapies drives demand for small-batch, complex API manufacturing, areas where CDMOs excel due to their flexibility and expertise. Growing collaborations between pharmaceutical firms and CDMOs also foster innovation and accelerate time-to-market, enabling companies to meet better evolving patient better needs.

The market presents significant opportunities, especially in developing biologics, gene therapies, and cell therapies requiring highly specialized API manufacturing. The trend toward continuous manufacturing and flow chemistry offers avenues for CDMOs to improve efficiency and scalability while reducing costs and environmental impact.

U.S. Active Pharmaceutical Ingredients CDMO Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the U.S. active pharmaceutical ingredients CDMO market report based on product, synthesis, drug, workflow, and application.

Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Traditional Active Pharmaceutical Ingredient
  • Highly Potent Active Pharmaceutical Ingredient
  • Antibody Drug Conjugate (ADC)
  • Other

Synthesis Outlook (Revenue, USD Million, 2018 - 2030)

  • Synthetic
  • Biotech

Drug Outlook (Revenue, USD Million, 2018 - 2030)

  • Innovative
  • Generic

Workflow Outlook (Revenue, USD Million, 2018 - 2030)

  • Clinical
  • Commercial

Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Oncology
  • Hormonal
  • Glaucoma
  • Cardiovascular disease
  • Diabetes
  • Others

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. Internal Database
1.3.3. Secondary Sources and Third-Party Perspectives
1.3.4. Primary Research
1.4. Information Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation and Data Visualization
1.6. Data Validation and Publishing
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Active Pharmaceutical Ingredients CDMO Market Variables, Trends and Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.2.3. Industry Challenge
3.3. Industry Analysis Tools
3.3.1. PORTER’s Analysis
3.3.1.1. Bargaining power of the suppliers
3.3.1.2. Bargaining power of the buyers
3.3.1.3. Threats of substitution
3.3.1.4. Threats from new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic and social landscape
3.3.2.3. Technological landscape
Chapter 4. U.S. Active Pharmaceutical Ingredients CDMO Market: Product Estimates and Trend Analysis
4.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Product: Key Takeaways
4.2. Product Movement Analysis and Market Share, 2024 and 2030
4.3. Market Estimates and Forecasts, By Product, 2018 - 2030 (USD Million)
4.3.1. Traditional Active Pharmaceutical Ingredient
4.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2. Highly Potent Active Pharmaceutical Ingredient
4.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3. Antibody Drug Conjugate (ADC)
4.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.4. Other
4.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. U.S. Active Pharmaceutical Ingredients CDMO Market: Synthesis Estimates and Trend Analysis
5.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Synthesis: Key Takeaways
5.2. Synthesis Movement Analysis and Market Share, 2024 and 2030
5.3. Market Estimates and Forecasts, By Synthesis, 2018 - 2030 (USD Million)
5.3.1. Synthetic
5.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.2. Biotech
5.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. U.S. Active Pharmaceutical Ingredients CDMO Market: Drug Estimates and Trend Analysis
6.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Drug: Key Takeaways
6.2. Drug Movement Analysis and Market Share, 2024 and 2030
6.3. Market Estimates and Forecasts, By Drug, 2018 - 2030 (USD Million)
6.3.1. Innovative
6.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2. Generic
6.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. U.S. Active Pharmaceutical Ingredients CDMO Market: Workflow Estimates and Trend Analysis
7.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Workflow: Key Takeaways
7.2. Workflow Movement Analysis and Market Share, 2024 and 2030
7.3. Market Estimates and Forecasts, By Workflow, 2018 - 2030 (USD Million)
7.3.1. Clinical
7.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. Commercial
7.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. U.S. Active Pharmaceutical Ingredients CDMO Market: Application Estimates and Trend Analysis
8.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Application: Key Takeaways
8.2. Application Movement Analysis and Market Share, 2024 and 2030
8.3. Market Estimates and Forecasts, By Application, 2018 - 2030 (USD Million)
8.3.1. Oncology
8.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.2. Hormonal
8.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.3. Glaucoma
8.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.4. Cardiovascular disease
8.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.5. Diabetes
8.3.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.6. Others
8.3.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Company Market Positioning
9.3. Company Heat Map Analysis
9.4. Company Profiles/Listing
9.4.1. Thermo Fisher Scientific Inc.
9.4.1.1. Company Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Portfolio
9.4.1.4. Recent Developments/ Strategic Initiatives
9.4.2. Novo Group (Catalent, Inc.)
9.4.2.1. Company Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Portfolio
9.4.2.4. Recent Developments/ Strategic Initiatives
9.4.3. Cambrex Corporation
9.4.3.1. Company Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Portfolio
9.4.3.4. Recent Developments/ Strategic Initiatives
9.4.4. Piramal Pharma Limited
9.4.4.1. Company Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Portfolio
9.4.4.4. Recent Developments/ Strategic Initiatives
9.4.5. Corden Pharma
9.4.5.1. Company Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Portfolio
9.4.5.4. Recent Developments/ Strategic Initiatives
9.4.6. Siegfried Holding AG
9.4.6.1. Company Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Portfolio
9.4.6.4. Recent Developments/ Strategic Initiatives
9.4.7. Seqens North America
9.4.7.1. Company Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Portfolio
9.4.7.4. Recent Developments/ Strategic Initiatives
9.4.8. SK pharmteco Inc.
9.4.8.1. Company Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Portfolio
9.4.8.4. Recent Developments/ Strategic Initiatives
9.4.9. Noramco.
9.4.9.1. Company Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Portfolio
9.4.9.4. Recent Developments/ Strategic Initiatives
9.4.10. BSP Pharmaceuticals
9.4.10.1. Company Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Portfolio
9.4.10.4. Recent Developments/ Strategic Initiatives
List of Tables
Table 1 List of abbreviations
Table 2 U.S active pharmaceutical ingredients CDMO market: key market driver analysis
Table 3 U.S active pharmaceutical ingredients CDMO market: Key market restraint analysis
Table 4 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by product (USD Million)
Table 5 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by synthesis (USD Million)
Table 6 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by drug (USD Million)
Table 7 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by workflow (USD Million)
Table 8 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by application (USD Million)
Table 9 Recent developments and impact analysis by key market participants
Table 10 Company heat map analysis, 2024
Table 11 Companies implementing key strategies
List of Figures
Fig. 1 U.S active pharmaceutical ingredients CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing and forecasting
Fig. 7 Parent market analysis
Fig. 8 Market formulation and validation
Fig. 9 U.S active pharmaceutical ingredients CDMO market snapshot
Fig. 10 U.S active pharmaceutical ingredients CDMO market segment snapshot
Fig. 11 U.S active pharmaceutical ingredients CDMO market competitive landscape snapshot
Fig. 12 Market research process
Fig. 13 Market driver relevance analysis (Current and future impact)
Fig. 14 Market restraint relevance analysis (Current and future impact)
Fig. 15 U.S active pharmaceutical ingredients CDMO market: Product outlook key takeaways (USD Million)
Fig. 16 U.S active pharmaceutical ingredients CDMO market: Product movement analysis 2024 & 2030 (USD Million)
Fig. 17 Traditional Active Pharmaceutical Ingredient market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 18 Highly Potent Active Pharmaceutical Ingredient market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 19 Antibody Drug Conjugate (ADC)s market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 20 Others market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 21 U.S active pharmaceutical ingredients CDMO market: Synthesis outlook key takeaways (USD Million)
Fig. 22 U.S active pharmaceutical ingredients CDMO market: Synthesis movement analysis 2024 & 2030 (USD Million)
Fig. 23 Synthetic market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 24 Biotech market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 25 U.S active pharmaceutical ingredients CDMO market: Drug outlook key takeaways (USD Million)
Fig. 26 U.S active pharmaceutical ingredients CDMO market: Drug movement analysis 2024 & 2030 (USD Million)
Fig. 27 Innovative market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 28 Generics market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 29 Distributed recipient drugs market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 30 U.S active pharmaceutical ingredients CDMO market: Workflow outlook key takeaways (USD Million)
Fig. 31 U.S active pharmaceutical ingredients CDMO market: Workflow movement analysis 2024 & 2030 (USD Million)
Fig. 32 Clinical market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 33 Commercial market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 34 U.S active pharmaceutical ingredients CDMO market: Application outlook key takeaways (USD Million)
Fig. 35 U.S active pharmaceutical ingredients CDMO market: Application movement analysis 2024 & 2030 (USD Million)
Fig. 36 Oncology market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 37 Hormonal market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 38 Glaucoma market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 39 Cardiovascular disease market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 40 Diabetes market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 41 Others market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 42 Strategy framework
Fig. 43 Company categorization

Companies Mentioned

  • Thermo Fisher Scientific Inc.
  • Novo Group (Catalent, Inc.)
  • Cambrex Corporation
  • Piramal Pharma Limited
  • Corden Pharma
  • Siegfried Holding AG
  • Seqens North America
  • SK pharmteco Inc.
  • Noramco.
  • BSP Pharmaceuticals

Table Information

Report AttributeDetails
No. of Pages80
PublishedJune 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 25.28 Billion
Forecasted Market Value ( USD ) by 2030 $ 33.86 Billion
Compound Annual Growth Rate5.1%
Regions CoveredUnited States
No. of Companies Mentioned10

Related Topics

Related Reports

Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product, By Synthesis, By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product, By Synthesis, By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 137 Pages
  • Global
From
China Small Molecule CDMO Market Size, Share & Trends Analysis Report By Product (Active Pharmaceutical Ingredients API, Finished Drug Products), By Synthesis, By Drug, By Workflow, And Segment Forecasts, 2023 - 2030 - Product Image

China Small Molecule CDMO Market Size, Share & Trends Analysis Report By Product (Active Pharmaceutical Ingredients API, Finished Drug Products), By Synthesis, By Drug, By Workflow, And Segment Forecasts, 2023 - 2030

  • Report
  • 100 Pages
  • China
From
Pharmaceutical CDMO Market Size, Share & Trends Analysis Report by Product (API, Drug Product), Workflow (Clinical, Commercial), Application (Oncology, Infectious Diseases, Neurological Disorders), Region, and Segment Forecasts, 2024-2030 - Product Image

Pharmaceutical CDMO Market Size, Share & Trends Analysis Report by Product (API, Drug Product), Workflow (Clinical, Commercial), Application (Oncology, Infectious Diseases, Neurological Disorders), Region, and Segment Forecasts, 2024-2030

  • Report
  • 342 Pages
  • Global
From
Semi-Solid Dosage CDMO Market Size, Share & Trends Analysis Report By Route of Administration (Topical, Transdermal), By Product, By Service, By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Semi-Solid Dosage CDMO Market Size, Share & Trends Analysis Report By Route of Administration (Topical, Transdermal), By Product, By Service, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 145 Pages
  • Global
From
Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type (Pharmaceutical, Biotechnology), By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type (Pharmaceutical, Biotechnology), By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.